After taking the drug, the tumor enlarges, indicating that the anti-cancer drug is not effective? Professor Wu Yilong: This new standard should be looked at

Lung cancer has always been the world's most common cancer on the list of malignant tumors, known as the "cancer boss".
in Europe and the United States, lung cancer is gradually catching up with and surpassing later.
the latest U.S. data show that lung cancer has fallen to "second cancer", with men and women ranked "first" in malignant tumors (30 percent) and prostate cancer (26 percent), respectively.
, the incidence of cancer in the United States has been gradually declining trend, with the decline in lung cancer is particularly pronounced.
This is a piece of content shared by Professor Wu Yilong, Life Director of Guangdong Provincial People's Hospital and Honorary Director of Guangdong Lung Cancer Research Institute, at the Recent Cross-Border Media Salon for Health Communication Cross-Border Experts - Frontiers of Pharmaceutical Innovation.
Wu Yilong reports on the significant decline in global cancer mortality from lung cancer prevention and innovative treatments, and the changes in the epidemiology of cancer in the United States, the largest credit for lung cancer, also represent global cancer trends.
despite the number of new cancer cases each year, the overall incidence and mortality rate of cancer is on the decline.
, the death rate from cancer has dropped significantly, with lung cancer contributing 46%.
, the decline in lung cancer mortality has directly led to a decline in cancer deaths worldwide.
why can lung cancer drive the global cancer "decline"? In his view, in addition to the positive effects of cancer prevention efforts, the decline in lung cancer morbidity and mortality also depends on a revolutionary breakthrough in treatment.
this has to be mentioned in the nearly 20 years of lung cancer treatment milestones, which in turn are the driving gene detection and the rise of immunotherapy is the most important.
, unlike the United States and the world, lung cancer still ranks first in the incidence of malignant tumors in China.
statistics, China accounts for one-third of all new lung cancer cases in the world each year, with 787,000 new lung cancer cases and 631,000 deaths in 2015.
to determine whether the drug is effective, no longer look at whether the tumor increases lung cancer has found eight driving genes, including EGFR gene, ALK gene, ROSI gene, BRAF gene, cMET gene, RET gene, KRAS gene, NTRK gene, can cause 8 different lung cancer.
these types of lung cancer, the efficiency of drug treatment can reach more than 70%, many patients live for more than three years.
" Chinese accounted for 40% of the EGFR gene mutation, there are now a variety of targeted drugs, imported domestic have.
" Wu Yilong said that lung cancer now not only has an effective drug, but also the domestic drug to play the catfish effect to bring down the price, the access to the drug greatly improved.
lung cancer patients with genetic mutations spend more than a hundred dollars a month on health insurance.
eight drive genes cause eight types of lung cancer, and the study of drug-based genes that are up to 70% effective (doctor PPT) brings about a big change that has upended past understandings of drug-stopping standards.
past, if the tumor grows after the patient has been on the drug, it means that the drug is not effective.
now believe that the drug should always be used to be insulable (too toxic) or not clinically useless.
" he explains, clinical benefits and tumor growth are two different concepts.
tumor does not mean drug resistance, only when the patient has the relevant clinical symptoms, it is considered that there is no clinical benefit.
the concept of drug use has greatly increased the duration of drug use, so that more patients can benefit more.
immunotherapy is a "god drug", the combined side effects will be greater CTLA-4 inhibition approved for the market, marking the rise of a new generation of immunotherapy drugs;
Immune therapy, represented by PD-1, increased the survival rate of patients with advanced non-small cell lung cancer by less than 5% to 16% in five years, with more and more amazing clinical data, and immunotherapy was thus known as the "anti-cancer drug".
with the rise of tumor co-treatment models, even immunotherapy, often have to be combined with other treatments, does this mean that immunotherapy is not so divine? "In the past, patients with advanced lung cancer could only survive for about a year at most, " says Mr Wu.
now have PD-1, the mortality rate has dropped significantly, and one-third of patients can survive long-term or even cure the tumor.
this was unthinkable in the past, so it's not too much to call immunotherapy a 'god medicine'.
" "But 'God's medicine' doesn't mean a hundred.
" he points out that immunotherapy also has its own limitations: "When it first used, single-drug efficiency was not particularly high, combined therapy can improve efficiency and overcome drug resistance problems, and some lung cancer patients can not benefit from immunotherapy, it is only effective for some patients."
is the key to cancer immunotherapy to determine which patients can benefit in the long term, which patients do not benefit in the long term, and what methods are needed to control the tumor.
"PD-L1 table PD-L1 expression classifys tumor patients and uses different immunotherapy options (Doctor PPT) for lung cancer applications, which are suitable for lung cancer patients without genetic mutations.
patients who are clinically driven by gene-negative are divided into three types, each with a different combination of immunotherapy.
combination of drugs has become a trend in the treatment of large cancers, the use of multiple drugs means that the side effects of drugs may be greater.
, Wu Yilong said, "Medically, I think simplicity is beauty."
can treat patients in a simpler way, the higher the level of the doctor.
can be cured with one medicine, don't use two medicines.
the more medicines you put together, the more side effects you have.
", patients and their families need not worry too much.
" current immunotherapy side effects can be controlled, preventable, treatable! He responded with a stoic response that since the first immunotherapy drug was launched in China in 2018, immunotherapy has been widely used in domestic hospitals, with a clear clinical understanding of the side effects of immunotherapy and a wealth of processing experience.
no matter where it occurs, the treatment of its side effects is one principle: to find a way to suppress excessive immunotherapy.
39 Health Network Source: 39 Health Network Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical, are not authorized, may not be reproduced by any media, website or individual, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here